公开(公告)号：US20220265823A1

公开(公告)日：2022-08-25

申请号：US17738846

申请日：2022-05-06

Applicant: Novartis AG

Inventor： Shinji HATAKEYAMA ,  Ronenn ROUBENOFF ,  Estelle TRIFILIEFF ,  Jerome FEIGE ,  Lloyd B. KLICKSTEIN

IPC: A61K39/395 ,  A61P21/00 ,  A61P35/00 ,  A61K33/243 ,  A61K31/436

Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment Especially, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.

公开(公告)号：US20180140582A1

公开(公告)日：2018-05-24

申请号：US15876619

申请日：2018-01-22

Applicant: NOVARTIS AG

Inventor： Jun CAO ,  Bernhard ERB ,  Robin Alec FAIRHURST ,  Arnaud GRANDEURY ,  Shinji HATAKEYAMA ,  Magdalena KOZICZAK-HOLBRO ,  Xinzhong LAI ,  Philipp LUSTENBERGER ,  Bernd Ulrich RIEBESEHL ,  Nicola TUFILLI ,  Thomas ULLRICH ,  Xiang WU ,  Jianguang ZHOU

IPC: A61K31/428 ,  C07C53/10 ,  C07D277/68 ,  A61K45/06 ,  A61K31/167

CPC classification number: A61K31/428 ,  A61K31/167 ,  A61K45/06 ,  C07B2200/07 ,  C07C53/10 ,  C07D277/68 ,  Y02P20/55

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

公开(公告)号：US20200181271A1

公开(公告)日：2020-06-11

申请号：US16626170

申请日：2018-06-26

Applicant: NOVARTIS AG

Inventor： Shinji HATAKEYAMA ,  Michaela KNEISSEL ,  Estelle TRIFILIEFF

IPC: C07K16/28 ,  A61P13/00

Abstract: The disclosure relates to novel uses and methods for preventing and/or treating urinary incontinence, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.